Search
Yersinia pestis 195/p antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB15461InvestigationalYersinia pestis 195/p antigen (formaldehyde inactivated) is under investigation in clinical trial NCT02596308 (Immunogenicity and Safety of Subunit Plague Vaccine).
Obatoclax
go.drugbank.com/drugs/DB12191InvestigationalObatoclax has been used in trials studying the treatment of AML, Leukemia, Myelofibrosis, Hodgkin's Lymphoma, and Mantle-Cell Lymphoma, among others.
LCP-AtorFen
go.drugbank.com/drugs/DB05769InvestigationalLCP-AtorFen is a fixed-dose combination therapy for the treatment of high cholesterol levels combining atorvastatin (the active ingredient of LipitorĀ®) and the lowest dose of fenofibrate without food effect. LCP-AtorFen is designed to be...
CVT-6883
go.drugbank.com/drugs/DB05936ExperimentalCVT-6883 is a selective, potent and orally available A2B-adenosine receptor antagonist which CV Therapeutics is investigating for the potential treatment of asthma and other conditions related to inflammation and fibrosis.
Otamixaban
go.drugbank.com/drugs/DB06635InvestigationalOtamixaban is a novel direct Factor Xa (FXa) inhibitor. It is currently being developed by the French pharmaceutical company Sanofi-Aventis as a treatment for acute coronary syndrome.
PEV3A
go.drugbank.com/drugs/DB05144InvestigationalPEV3A is a prophylactic malaria vaccine that acts against various stages of the disease. It is a two-component vaccine that contains the virosome formulated peptide mimetics PEV301 and PEV302. The two synthetic peptide vaccine components...